Pharma Divestiture Wolters Kluwer Divests Its Pharma Business

Editor: Dominik Stephan

Dutch health care specialist Wolters Kluwer will divest its pharma solutions business. The company announced a new strategy to focus on core health markest in content and clinical support solutions.

Related Companies

(Picture: Wolters Kluwer)
(Picture: Wolters Kluwer)

Alphen aan den Rijn/The Netherlands – With the company regards this step as a shift of its strategic focus as a health care service supplier. Wolters Kluwer expects to profit from recent reform trends on the health care market as Nancy McKinstry, CEO and Chairman of Wolters Kluwer's Executive Board, states: "The planned divestment of the Pharma business will focus our Health division on taking full advantage of our leading positions in professional information and clinical decision support solutions, one of the fastest growing areas of Health, to deliver enhanced value to our stakeholders.”

Wolters Kluwers pharma solutions provides marketing and publications services, business intelligence products as well as analytical tools and services to support life sciences professionals. Bob Becker, CEO of Wolters Kluwer Health & Pharma Solutions, expects divestiture to close around or shortly after the end of the year. The divestiture will be accompanied by the financial advisory of Lazard Middle Market and William Blair & Company. “Moving forward, we are excited about continued opportunities to deliver value to global customers through our portfolio of leading brands in content and clinical decision support, which are well-positioned to benefit from healthcare reform trends globally to support the division’s growth strategy," said Becker.